IBRANCE (palbociclib) Recommended Dose Modifications for Adverse Reactions

This tool was designed to help you assess the grade of the adverse event reported by your patient and to get dosing modifications recommendations based on the grade of the event as per the approved IBRANCE Prescribing Information.

  • Step 1: select an adverse event (see most common adverse reactions below, please use our search functionality or switch to view the full list)
  • Step 2: assess the grade of the adverse event as per CTCAE 4.0 criteria
  • Step 3: determine appropriate dosing modifications strategies

If you need additional information (including the incidence of the adverse events occurring in the pivotal palbociclib randomized clinical trials), please consult the approved IBRANCE® capsules Prescribing Information or IBRANCE® tablets Prescribing Information, search through our collection of approved scientific response documents or contact us directly ( submit a request online, or call 1-800-438-1985).

The recommended dose of IBRANCE is a 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Dosing interruption and/or dose reductions for IBRANCE are recommended based on individual safety and tolerability. Please refer to the full IBRANCE® capsules Prescribing Information or IBRANCE® tablets Prescribing Information for the coadministered endocrine therapy for dosing recommendations and dose adjustment guidelines in the event of toxicity.

Pfizer is unable to make any specific dosage and/or treatment recommendations for individual patients beyond palbociclib dosage modifications as described in the IBRANCE Prescribing Information; clinical judgment based on the medical history and the clinical status of a specific patient will dictate the appropriate actions to be taken.